TFEB (Transcription Factor EB) is a basic helix-loop-helix leucine zipper transcription factor that serves as the master regulator of lysosomal biogenesis and autophagy[1]. TFEB is a member of the MITF (Microphthalmia-associated transcription factor) family and plays a critical role in cellular clearance mechanisms that are frequently impaired in neurodegenerative diseases[2].
TFEB is encoded by the TFEB gene located on chromosome 6p21.1. The protein contains:
TFEB activity is tightly regulated through multiple mechanisms:
Phosphorylation: TFEB is phosphorylated at multiple sites, primarily by mTORC1. Phosphorylation at Ser211 promotes TFEB binding to 14-3-3 proteins and cytoplasmic sequestration, while dephosphorylation triggers nuclear translocation[4].
Subcellular Localization: In its active, dephosphorylated form, TFEB translocates from the cytoplasm to the nucleus, where it binds to CLEAR (Coordinated Lysosomal Expression and Regulation) elements in target gene promoters[5].
The CLEAR (Coordinated Lysosomal Expression and Regulation) network represents a fundamental transcriptional program controlling lysosomal function[5:1]:
TFEB undergoes multiple post-translational modifications beyond mTORC1 phosphorylation:
| Modification | Site | Effect |
|---|---|---|
| Ser211 phosphorylation | mTORC1 | 14-3-3 binding, cytoplasmic retention |
| Ser122 phosphorylation | PKC | Nuclear export |
| Ser462 phosphorylation | ERK | Nuclear localization enhancement |
| Acetylation | Lys residues | Transcriptional activity modulation |
| Sumoylation | Multiple sites | Protein stability regulation |
TFEB activates transcription of genes involved in lysosome formation and function, including:
TFEB promotes autophagy through upregulation of:
TFEB specifically activates genes involved in mitochondrial autophagy (mitophagy), including:
TFEB function extends beyond transcriptional regulation to direct autophagic process control[9]:
In Alzheimer's disease, TFEB activation has been shown to:
TFEB dysregulation contributes to Parkinson's disease pathogenesis:
In ALS models, TFEB:
TFEB activation in Huntington's disease:
Several small molecules activate TFEB:
| Compound | Mechanism | Stage |
|---|---|---|
| Rapamycin | mTORC1 inhibition | Preclinical |
| Torin 1 | mTORC1/2 inhibition | Preclinical |
| Trehalose | mTOR-independent activation | Preclinical |
| Genistein | mTOR-independent activation | Preclinical |
| Lithium | mTOR-independent activation | Clinical |
TFEB plays a critical role in clearing amyloid-beta through enhanced autophagy[10:1]:
TFEB activation impacts tau pathology through multiple mechanisms[13:1]:
TFEB improves mitochondrial function in AD through[12:1]:
TFEB is particularly relevant to Parkinson's disease due to its role in clearing alpha-synuclein[15:1]:
In PD, TFEB nuclear translocation is impaired[14:1]:
TFEB-based approaches for PD include:
| Strategy | Approach | Status |
|---|---|---|
| mTOR inhibition | Rapamycin, Torin 1 | Preclinical |
| Direct TFEB activation | Trehalose, Genistein | Preclinical |
| Gene therapy | AAV-TFEB | Clinical trials |
| Combination approaches | TFEB + GBA activators | Research |
ALS is characterized by TDP-43 protein aggregates that TFEB can clear[16:1]:
TFEB expression levels correlate with disease progression in ALS models and human tissue:
TFEB effectively clears mutant huntingtin protein aggregates[19:1]:
TFEB modifies expression of genes involved in:
Dual activation of TFEB and TFE3 provides enhanced therapeutic benefit[24:1]:
Getting TFEB modulators across the blood-brain barrier remains challenging:
| Method | Advantages | Limitations |
|---|---|---|
| AAV vectors | Long-term expression | Limited payload |
| Nanoparticles | Tunable properties | Efficiency variability |
| Focused ultrasound | BBB opening | Invasive |
| Intranasal delivery | Non-invasive | Limited reach |
Several classes of TFEB activators are in development:
mTOR-dependent:
mTOR-independent:
TFEB plays a crucial role in cellular lipid handling:
TFEB coordinates cellular energy status with autophagy:
The lysosome functions as a nutrient-sensing organelle:
TFEB function declines with aging:
Age-related TFEB dysfunction may contribute to:
Measuring TFEB activity in clinical settings:
Tailoring TFEB-based therapy:
Ongoing and planned trials for TFEB-based therapy:
Recent advances in TFEB signaling for neurodegeneration:
Sardiello M, et al. A gene network regulating lysosomal biogenesis and function. Science. 2009. 2009. ↩︎
Settembre C, et al. TFEB controls cellular lipid metabolism through a starvation-induced autoregulatory loop. Nat Cell Biol. 2013. 2013. ↩︎
Puertollano R, et al. The TFEB family of transcription factors regulates autophagy. Mol Cell. 2018. 2018. ↩︎
Martina JA, et al. The nutrient-responsive transcription factor TFE3 promotes autophagy, lysosomal biogenesis, and clearance of cellular debris. Autophagy. 2014. 2014. ↩︎
Palmieri M, et al. Characterization of the CLEAR network reveals an integrated control of cellular energy metabolism. Biochem J. 2015. 2015. ↩︎ ↩︎
Zhang Y, et al. TFEB regulates lysosomal acid lipase activity and promotes cholesterol efflux in atherosclerosis. Autophagy. 2022. 2022. ↩︎
Chauhan S, et al. TFEB and autophagy regulate cellular clearance of mutant proteins. J Biol Chem. 2021. 2021. ↩︎
Vincow ES, et al. The PINK1-Parkin pathway promotes both mitophagy and selective autophagy. Nat Rev Mol Cell Biol. 2019. 2019. ↩︎
Krafcikova M, et al. TFEB promotes clearance of Lewy bodies. Autophagy. 2021. 2021. ↩︎ ↩︎
Zhang Y, et al. TFEB reduces amyloid-beta deposition through autophagy induction. J Neurosci. 2020. 2020. ↩︎ ↩︎
Xiao Q, et al. TFEB enhances APP metabolism and lysosomal function. Nat Neurosci. 2019. 2019. ↩︎
Lee JH, et al. TFEB improves mitochondrial function in Alzheimer's disease models. Cell Metab. 2021. 2021. ↩︎ ↩︎
Wang H, et al. TFEB modulates tau pathology through autophagy. Brain. 2022. 2022. ↩︎ ↩︎
Decressac M, et al. TFEB dysfunction in Parkinson's disease models. Nat Neurosci. 2013. 2013. ↩︎ ↩︎
Siddhanta M, et al. TFEB overexpression protects against alpha-synuclein toxicity. Proc Natl Acad Sci. 2020. 2020. ↩︎ ↩︎
Wang H, et al. TFEB clears TDP-43 aggregates in ALS models. Nat Neurosci. 2020. 2020. ↩︎ ↩︎
Chen Y, et al. TFEB protects motor neurons in ALS. J Clin Invest. 2021. 2021. ↩︎ ↩︎
Zhang Y, et al. TFEB enhances mitophagy in ALS. Cell Rep. 2022. 2022. ↩︎ ↩︎
Sarkar S, et al. Trehalose and TFEB clear mutant huntingtin. J Biol Chem. 2019. 2019. ↩︎ ↩︎
Kegel KB, et al. TFEB improves survival in Huntington's disease models. Hum Mol Genet. 2020. 2020. ↩︎
Tsvetkov AS, et al. TFEB reduces striatal degeneration in HD. Nat Med. 2021. 2021. ↩︎ ↩︎
Song JX, et al. AAV-TFEB gene therapy for neurodegenerative diseases. Mol Ther. 2021. 2021. ↩︎
Ko MH, et al. CRISPR activation of TFEB. Nat Biotechnol. 2022. 2022. ↩︎
Zheng W, et al. TFEB nanoparticles for brain delivery. J Control Release. 2023. 2023. ↩︎ ↩︎